BioXplor has exposed part of it's biomedical knowledge platform to accelerate the discovery of actionable insights from the torrent of COVID-19 literature. The COVID-19 Discovery Engine is completely open-access and supported by COVID-19 response grants, programs & partnerships with EIT Health (European Innovation and Technology Institute), Creative Destruction Labs @ University of Oxford, and University of Manitoba /MITACS (Haigh Laboratory). The COVID-19 Discovery Engine is being further developed as part of a collaboration with a team of international experts on a Royal Society of Chemistry book (in draft) 'Translational Toxicology of Antiviral Agents -- The COVID-19 Pandemic and the Future'.
The engine is one of most comprehensive resources for ontology-based knowledge discovery & text mining in COVID-19. It combines structured content from over 100,000 COVID-19 related full-text scientific papers from the CORD-19 dataset including PubMed, WHO, Elsevier, PubMed Central, BioRxiv, MedRxiv, using 30+ proprietary biomedical ontology dictionaries to enable scientists to discover insights up to 25X faster than Google Scholar or Pubmed.
Free Access Here
COVID-19 Open Access Text Mining Engine
SARS-CoV-2 Viral Variant Tracker & Primer Design Tool
BioXplor is collaborating with the University of Manitoba to develop and distribute a computational platform to track SARS-CoV-2 viral variants in different populations via sequencing data analysis. BioXplor is offering a service to Oligo manufacturers and RT-PCR kit mnaufacturers to integrate it's Virus Mutation Visual Analysis Platform, as well as offering Primer Design Services to identify the optimal primers for RT-PCR diagnostic test kits, since false-negatives can be caused due to founder mutation effects in current primer design sites (including CDC primers). In the BioArxiv paper: "early mutational events are described across samples from publicly available SARS CoV-2 sequences from the sequence reads, mostly from China, USA (Washington DC) and Australia 30 (Victoria). 90% of datasets contain at least a single founder mutation and most of the variants are missense (over 63%). Five-point mutations with clonal (founder) effect were found in USA sequencing samples. Australian mutation signatures were more diverse than USA samples."
Access Bioarxiv Paper